The American College of Obstetricians and Gynecologists (ACOG) announced a new education campaign aimed at reducing deaths from colorectal cancer among women. Colorectal cancer is the No. 2 cancer killer of adults in the US and the third leading cause of cancer death among women in the US, behind lung and breast cancers.
The National Human Genome Research Institute (NHGRI) and the National Cancer Institute (NCI), parts of the National Institutes of Health (NIH), have teamed with Group Health Cooperative in Seattle and Henry Ford Health System in Detroit to launch a study to investigate the interest level of healthy, young adults in receiving genetic testing for eight common conditions.
Patients around the world face stark inequalities in access to cancer treatment, according to a report published today (Thursday 10 May) in the cancer journal, Annals of Oncology. The report’s authors urge decision makers in every country to take action and ensure that everyone has equal access to new cancer drugs when they are needed, wherever they live.
The American Gastroenterological Association (AGA) Institute is eager to increase the number of patients who receive screening for colon cancer. There are a variety of established screening methods that are widely available, and emerging technologies, such as computed tomography colonography (CT colonography), that are under investigation.
A new study says targeting smaller (??5 mm) lesions does little to significantly reduce the incidence of colorectal cancer (CRC) and, in fact, results in extremely high financial costs and a large proportion of adverse events.
Correcting social, economic and health-care inequalities may have the most significant impact in reducing survival differences in colorectal cancer between African-Americans and Caucasians, according to a new study.
Genentech and FDA notified healthcare professionals of important new safety information regarding tracheoesophageal (TE) fistula formation in a recent clinical study in patients with limited-stage small cell lung cancer (SCLC).
Financial incentives for physicians mean better care for patients, according to a six-year study of a large preferred provider organization in Hawaii.
Mutations in the KRAS oncogene could predict a lack of response to the drug cetuximab in patients with colorectal tumors. For those with the mutations, the drug is likely to be inefficient and possibly harmful, according to researchers at France?s Institut National de la Sante et de la Recherche Medicale (INSERM).
A daily dose of adult-strength aspirin may modestly reduce cancer risk in populations with high rates of colorectal, prostate, and breast cancer if taken for at least five years.